[144] Incyte Genomics Inc SEC Filing

Rhea-AI Filing Summary

Luther King Capital Management Corp. (LKCM) and its founder, J. Luther King, Jr., have filed Amendment No. 6 to Schedule 13G for scPharmaceuticals Inc. (SCPH) dated 30 Jun 2025. The filing discloses continued beneficial ownership above the 5 % threshold:

• LKCM reports 3,541,170 common shares with sole voting and dispositive power, representing 6.7 % of SCPH’s outstanding stock.
• J. Luther King, Jr. individually reports 3,669,170 common shares (sole voting/dispositive power) for a 7.0 % stake.

The amendment confirms that the shares are held in the ordinary course of business and not for the purpose of influencing control of the issuer. Both reporting persons classify as an “Investment Adviser” (LKCM) and “Individual” (King) under Rule 13d-1(b). No joint filing or group status is claimed, and there are no shared voting or dispositive powers.

Implications for investors: 1) LKCM remains one of SCPH’s larger institutional holders, potentially signaling confidence in the company’s prospects. 2) Because the ownership level is stable at ~7 %, the amendment itself does not suggest an imminent change in strategic direction or control. 3) Any future movement above or below the 5 % threshold would trigger additional filings, providing transparency on LKCM’s trading activity.

Positive

• Significant passive stake maintained: LKCM and its founder still control roughly 7 % of SCPH, indicating continued institutional confidence.

Negative

• Potential overhang risk: A 7 % holder could create selling pressure if LKCM decides to exit, though no such intent is stated.

Insights

Buy-Side Portfolio Manager

TL;DR: LKCM re-affirms ≈7 % SCPH stake; neutral impact, signals ongoing institutional support without control intent.

LKCM’s 3.5 M-share position (6.7 %) and King’s 3.7 M (7.0 %) confirm a meaningful, yet passive, ownership block. The absence of shared voting rights and the certification of non-control intent suggest LKCM remains a traditional, long-only holder rather than an activist. For existing shareholders, this provides a modest vote of confidence and liquidity support but does not alter SCPH’s strategic trajectory. The filing is routine—an amendment required as positions or share counts change modestly—so market impact should be limited.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	3706	251785.64	193569934	07/21/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	07/15/2025	Restricted Stock	ISSUER			1877	07/15/2025	Not Applicable
Common	07/14/2025	Restricted Stock	ISSUER			1829	07/14/2025	Not Applicable

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
STEVEN STEIN 1801 Augustine Cut-Off Wilmington DE 19803	Common	07/14/2025	11332	775864.64
STEVEN STEIN 1801 Augustine Cut-Off Wilmington DE 19803	Common	07/14/2025	3620	247849.45

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

Why did LKCM file an Amendment 6 Schedule 13G for SCPH?

To update its passive ownership disclosure, confirming a 6.7 % stake as of 30 Jun 2025.

How many scPharmaceuticals shares does J. Luther King, Jr. own?

He reports 3,669,170 common shares, representing 7.0 % of SCPH.

Is LKCM seeking control of scPharmaceuticals?

No. The certification states the shares are held in the ordinary course and not to influence control.

What triggers future 13G/13D filings for SCPH?

Any ownership change that moves LKCM above or below key thresholds (5 %, or 1 % increments thereafter) requires an updated filing.

Does the filing indicate a change in SCPH’s strategy or governance?

The filing is passive; it does not signal any strategic or governance changes at SCPH.